Abstracts tagged "patient outcomes"

Abstract Number: 1261 • 2017 ACR/ARHP Annual Meeting
The Effects of Disease Burden, Helplessness, and Pain on Depressive Symptoms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Sera Ramadan¹, Perry M. Nicassio², George Karpouzas³ and Sarah Ormseth⁴, ¹Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ²Cousins Center for PNI, UCLA, LA, CA, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: This research tested an integrated framework examining patient global assessment of disease activity (PtGA), maladaptive illness beliefs and pain as determinants of mood disturbance…
Abstract Number: 1692 • 2016 ACR/ARHP Annual Meeting
Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Jessica Mounessa¹, Darren Lynn¹, Jessica Walsh², Mena Hashim¹, Ryan Duong³, Robert Dellavalle¹ and Liron Caplan¹, ¹Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO
Background/Purpose: While the psoriasis area and severity index (PASI) is the most commonly used assessment tool for psoriasis severity, it has been criticized for its…
Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Jürgen Braun¹ and ASAS HI international validation study, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…
Abstract Number: 95 • 2016 ACR/ARHP Annual Meeting
An Analysis of Malpractice Litigation in Rheumatology
Arpan Prabhu¹, Raghav Gupta², Ranjit Thomas³ and Chester V. Oddis⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Rutgers New Jersey Medical School, Newark, NJ, ³Tufts University, Medford, MA, ⁴Rheumatology/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Medicine is an increasingly more litigious environment, and the probability of a practitioner facing a medical malpractice claim is high. Given the tumultuous liability…
Abstract Number: 2041 • 2016 ACR/ARHP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
Shanthini Kasturi¹, Jayme C. Burket², Jessica Berman¹, Kyriakos A. Kirou¹, Alana B. Levine¹, Lisa R. Sammaritano¹ and Lisa Mandl¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: The measurement of patient reported outcomes (PROs) is a growing priority for performance improvement in clinical care of chronic conditions such as SLE. Measuring…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
Abstract Number: 2515 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)
Vibeke Strand¹, Kathy Lampl², Christine Birchwood³, Jinglan Pei², Katie Tuckwell⁴, Rebecca Finch⁴, Cem Gabay⁵, Arthur Kavanaugh⁶ and Graeme Jones⁷, ¹Stanford University School of Medicine, Palo Alto, CA, ²Genentech, Inc., South San Francisco, CA, ³1 DNA Way, MS# 304, Genentech, Inc., South San Francisco, CA, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Rheumatology, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁶University of California San Diego, La Jolla, CA, ⁷Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Patient-reported outcomes (PROs) are important measures when determining response to therapy in patients with RA. Previous RCTs have shown that TCZ monotherapy is superior…
Abstract Number: 546 • 2016 ACR/ARHP Annual Meeting
Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Gulsen Ozen¹, Ali Ugur Unal², Haner Direskeneli³ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Patient global assessment (PtGA), despite not being exclusively related to disease activity, is included in Boolean-based remission (BR) criteria for RA. This study evaluated…
Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Ben Roberts¹, Alexander Langridge², John Wilkinson³, Elliot Jones⁴, Edward Lea², Ben Hargreaves⁵, David Walker⁶ and Martin Lee³, ¹Rheumatology, Newcastle University, Newcastle, United Kingdom, ²Rheumatology, Freeman Hospital, Newcastle, United Kingdom, ³Freeman Hospital, Newcastle, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶Rake Lane, Northumbria Healthcare, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
Abstract Number: 854 • 2016 ACR/ARHP Annual Meeting
The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma
Cosimo Bruni¹, Tanaka Ngcozana², Francesca Braschi³, Guya Piemonte⁴, Laura Benelli⁴, Serena Guiducci⁵, Silvia Bellando-Randone³, Jonathan Grotts⁶, Christopher Denton⁷, Daniel E. Furst⁸ and Marco Matucci-Cerinic⁵, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ³Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁴University of Florence, Florence, Italy, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁶Biostatistics, University of California Los Angeles, Los Angeles, CA, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁸Division of Rheumatology, Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: No objective measure is presently available to assess digital ulcer (DU) in SSc patients apart from “healed/non healed” and experience-based clinical judgment. The aim…
Abstract Number: 2750 • 2016 ACR/ARHP Annual Meeting
Concordance Between Patient and Physician Global Assessment of the Disease in Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Osvaldo Luis Cerda², Margarita Landi², Cecilia Zaffarana², Emilce Schneeberger² and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: In Rheumatoid Arthritis it has been observed a significant discrepancy in the global assessment of the disease by the patient and physician and this…
Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², Gunnar Tomasson³, Joshua F. Baker⁴, David Cuthbertson⁵, Renee Borchin⁶, Simon Carette⁷, Lindsy J. Forbess⁸, Gary S. Hoffman⁹, Nader A. Khalidi¹⁰, Curry L. Koening¹¹, Carol A. McAlear¹², Paul A. Monach¹³, Larry W. Moreland¹⁴, Christian Pagnoux¹⁵, Philip Seo¹⁶, Robert F. Spiera¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg², Carol A. Langford¹⁹ and Peter A. Merkel²⁰, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶University of South Florida, Tampa, FL, ⁷Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ¹¹Rheumatology, University of Utah, Salt Lake City, UT, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁶Medicine, Johns Hopkins University, Baltimore, MD, ¹⁷Hospital for Special Surgery, Cornell, New York, NY, ¹⁸Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²⁰Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].